Protein / target
Glycine receptor subunit beta
Protein at a glance
Biological role
Glycine-gated chloride channel
Primary biology
Neuronal / synaptic signalling
Strongest disease association
Hyperekplexia 2
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Subunit of heteromeric glycine-gated chloride channels.
View complete UniProt function annotationHide complete annotation
Subunit of heteromeric glycine-gated chloride channels (PubMed:11929858, PubMed:15302677, PubMed:16144831, PubMed:22715885, PubMed:23238346, PubMed:25445488, PubMed:34473954, PubMed:8717357). Plays an important role in the down-regulation of neuronal excitability (PubMed:11929858, PubMed:23238346). Contributes to the generation of inhibitory postsynaptic currents (PubMed:25445488)
Subcellular location
Domains and Gene Ontology detail (22)Hide
Gene Ontology
- Ccytoplasm
- Cdendrite
- CGABA-ergic synapse
- Cglycine-gated chloride channel complex
- Cglycinergic synapse
- Cplasma membrane
- Cpostsynaptic membrane
- Cpostsynaptic specialization
- Fexcitatory extracellular ligand-gated monoatomic ion channel activity
- Fextracellularly glycine-gated chloride channel activity
- Fextracellularly glycine-gated ion channel activity
- Fglycine binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Inhibitory neurotransmission
- ·Subunit of heteromeric glycine-gated chloride channels (PubMed:11929858, PubMed:15302677…
- ·GABA-ergic synapse
- ·glycinergic synapse
- ·synaptic transmission, glycinergic
Chloride transport
- ·Subunit of heteromeric glycine-gated chloride channels (PubMed:11929858, PubMed:15302677…
- ·glycine-gated chloride channel complex
- ·extracellularly glycine-gated chloride channel activity
Ion channel gating
- ·excitatory extracellular ligand-gated monoatomic ion channel activity
- ·extracellularly glycine-gated ion channel activity
- ·transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic…
Ligand-gated signalling
- ·excitatory extracellular ligand-gated monoatomic ion channel activity
- ·extracellularly glycine-gated ion channel activity
- ·transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic…
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Glycine receptor (alpha-1/beta) positive modulator
Glycine receptor (alpha-1/beta) positive modulator
Glycine receptor (alpha-1/beta) positive modulator
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene GLRB
Gene-level evidence surfaced through the gene GLRBthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (3)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
6 compounds recorded · 6 approved
View all recorded compounds (6)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (10)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationNeonatal sevoflurane exposures inhibits DHHC5-mediated palmitoylation of TfR1 in oligodendrocytes, leading to hypomyelination and neurological impairments.
- New publicationEarly exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.
- New publicationSharp wave-associated high-frequency oscillation (200 Hz) in the intact hippocampus: network and intracellular mechanisms.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Related family literature
Papers about “Receptors, Glycine” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.
Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.